✦ LIBER ✦

Physiologically Based Pharmacokinetic Modeling of Drug Disposition in Rat and Human: A Fuzzy Arithmetic Approach

✍ Scribed by Kok-Yong Seng; Ivan Nestorov; Paolo Vicini

Publisher: Springer US
Year: 2008
Tongue: English
Weight: 612 KB
Volume: 25
Category: Article
ISSN: 0724-8741
DOI: 10.1007/s11095-007-9447-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Modeling and Simulation of Hepatic Drug

Modeling and Simulation of Hepatic Drug Disposition Using a Physiologically Based, Multi-agent In Silico Liver

✍ Li Yan; Glen E. P. Ropella; Sunwoo Park; Michael S. Roberts; C. Anthony Hunt 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 539 KB

Determination of the rat tissue partitio

Determination of the rat tissue partitioning of endotoxin in vitro for physiologically-based pharmacokinetic (PBPK) modeling

✍ Ivan A. Ross; Philip P. Sapienza; Darcy E. Hanes; Widmark Johnson; Chung S. Kim 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 96 KB

## Abstract The biosynthetically double‐labeled lipopolysaccharide (LPS), containing ^3^H‐labeled on the fatty acyl‐chains and ^14^C‐labeled on the glucosamine of __Salmonella enterica serotype typhimurium__, was isolated from bacteria grown in proteose peptone‐beef extract (PPBE) medium in the pre

Utility of a physiologically–based pharm

Utility of a physiologically–based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug–drug–disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice

✍ Joseph A. Grillo; Ping Zhao; Julie Bullock; Brian P. Booth; Min Lu; Kathy Robie- 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 535 KB

Background: Rivaroxaban is an oral Factor Xa inhibitor. The primary objective of this communication was to quantitatively predict changes in rivaroxaban exposure when individuals with varying degrees of renal impairment are co-administered with another drug that is both a P-gp and a moderate CYP3A4

Application of physiologically based pha

Application of physiologically based pharmacokinetic modeling and clearance concept to drugs showing transporter-mediated distribution and clearance in humans

✍ Takao Watanabe; Hiroyuki Kusuhara; Yuichi Sugiyama 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 497 KB

PHRMA CPCDC initiative on predictive mod

PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: Prediction of plasma concentration–time profiles in human by using the physiologically-based pharmacokinetic modeling approach

✍ Patrick Poulin; Rhys D. O. Jones; Hannah M. Jones; Christopher R. Gibson; Malcol 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 529 KB

Investigation of 5-FU disposition after

Investigation of 5-FU disposition after oral administration of capecitabine, a triple-prodrug of 5-FU, using a physiologically based pharmacokinetic model in a human cancer xenograft model: comparison of the simulated 5-FU exposures in the tumour tissue between human and xenograft model

✍ Yuko Tsukamoto; Yukio Kato; Masako Ura; Ikuo Horii; Tohru Ishikawa; Hideo Ishits 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 274 KB 👁 2 views

## Abstract The nonlinear pharmacokinetics of capecitabine, a triple prodrug of 5‐FU preferentially activated in tumour tissues, was investigated in human cancer xenograft models. A physiologically based pharmacokinetic (PBPK) model integrating the activation process of capecitabine to 5‐FU and 5‐F